Clinical trial management firm BioClinica of Oxford, U.K., will partner with medical imaging software developer Mirada Medical to integrate Mirada's image analysis systems into BioClinica's PET and molecular imaging processes, the companies said.
Mirada's XD3 analysis software will be integrated into BioClinica's imaging core lab technology for PET and molecular imaging in oncology and other therapeutic areas.
Mirada's software provides tools for quantifying and tracking findings for PET, CT, MR, PET/MR, and other modalities, the companies said. BioClinica chose Mirada for its advanced image analysis capabilities and the ability to handle multiple modalities, which will enhance BioClinica's image registration and fusion capabilities in multimodality studies.
Mirada will present at BioClinica's user conference to be held in October in Philadelphia.
